ClinicalTrials.gg
WithdrawnNCT05465902Updated Mar 28, 2025

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster

A Phase 2 interventional study of Recombinant COVID-19 variant Vaccine (Sf9 Cell) and COVID-19 Vaccine (Vero Cell), Inactivated in COVID-19 and SARS-CoV-2 Infection, sponsored by WestVac Biopharma Co., Ltd.. Withdrawn at 1 site in Mexico. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by WestVac Biopharma Co., Ltd. · Phase 2, Interventional, and Prevention

How we know

Why this study was withdrawn
Clinical trials not conducted

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in COVID-19 by WestVac Biopharma Co., Ltd. — 3 open to participants now, 3 under way, 2 of them phase 3. COVID-19 · WestVac Biopharma Co., Ltd..

Enrollment
10th of 11
0 · median 450
Started
2023
with 3 others
Phase 2
4 of 11
1 open now
Registered
4th of 11
by date

Among the 11 studies in COVID-19 by WestVac Biopharma Co., Ltd., this one is the 10th largest by enrollment, is one of 4 that started in 2023, is one of 4 in phase 2, and was the 4th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 11 studies in COVID-19 by WestVac Biopharma Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in COVID-19 by WestVac Biopharma Co., Ltd., or all of them as a file.
02

Study summary

This is a randomized, phase Ⅱ, single-blind, randomized, parallel-group controlled clinical trial.

The study plans to enroll subjects who have completed homologous primary vaccination with either inactivated or mRNA or Viral Vector COVID-19 vaccines (one or two doses) and have not been infected with COVID-19. All subjects will be evaluated for safety and immunogenicity after a single dose booster immunization with Recombinant COVID-19 variant Vaccine (Sf9 Cell) or inactivated COVID-19 vaccine (Vero cell) or mRNA vaccine or Viral Vector vaccine.

Read the detailed description

This is a randomized, phase Ⅱ, single-blind, randomized, parallel-group controlled clinical trial.

The study plans to enroll subjects who have completed homologous primary vaccination with either inactivated or mRNA or Viral Vector COVID-19 vaccines (one or two doses) and have not been infected with COVID-19. All subjects will be evaluated for safety and immunogenicity after a single dose booster immunization with Recombinant COVID-19 variant Vaccine (Sf9 Cell) or inactivated COVID-19 vaccine (Vero cell) or mRNA vaccine or Viral Vector vaccine. The study plans to enroll about 600 subjects aged 18 years and above (subjects aged ≥ 60 years account for approximately 10%) that would be divided into three cohorts according to different primary vaccination: Inactivated COVID-19 vaccines cohort, mRNA COVID-19 vaccines cohort and Viral Vector COVID-19 vaccines cohort, with approximately 200 cases in each cohort. The subjects will be randomized to the Recombinant COVID-19 variant Vaccine (Sf9 Cell) group (test group) or the inactivated COVID-19 vaccine (Vero cell) group or mRNA vaccine or Viral Vector vaccine (control group) in a ratio of 1:1.

03

Conditions studied

  • COVID-19
  • SARS-CoV-2 Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Voluntarily sign the ICF approved by the Ethics Committee and agree to participate in the study before any study procedure.
    1. Healthy males or females able to provide legal identification, aged 18 years and above at the time of signing ICF.
    1. Subjects who have completed homologous primary vaccination with either Inactivated or mRNA or Viral Vector COVID-19 vaccines (full approval, CMA or EUA) and have the last dose administered 6 months ago or earlier from the date of signing the ICF for the study. Those who have received combined immunization with two doses of vaccines should be excluded.
    1. Able to communicate well with the investigator, and able to understand and comply with the requirements of this clinical trial.
    1. Males with female sexual partners or females of voluntarily take effective methods from signing ICF to 3 months after the vaccination, including sexual abstinence or effective contraceptive measures (e.g., intrauterine or implanted contraceptive device, oral contraceptives, injected or implanted contraceptives, sustained-release topical contraceptives, intrauterine device (IUD), condoms (male), diaphragm, and cervical cap).
    1. Axillary temperature \<37.3℃.

Exclusion criteria

Exclusion Criteria:

    1. Positive SARS-CoV-2 RT-PCR at screening.
    1. Prior medical history of Serve Acute Respiratory Syndromes (SARS), Middle East Respiratory Syndrome (MERS) and other human coronavirus infections or diseases.
    1. Prior history or family history of convulsion, epilepsy, encephalopathy and psychosis.
    1. Fear of needles.
    1. Pregnant or lactating females or those who plan to become pregnant or donate eggs during study period.
    1. Prior history of allergic reaction or anaphylaxis to any vaccine or its , e.g., , urticaria, serious eczema, dyspnea, laryngeal edema, and angioedema etc..
    1. Prior use of any vaccine within 28 days before receiving this vaccine or planning to use any vaccine other than this investigational vaccine during the study period.
    1. Participation in studies of any other interventional device or drug within 28 days before the screening, or current treatment with other investigational drug(s) or within 5 half-lives after taking the last dose of the study drug.
    1. Hereditary hemorrhagic tendency or coagulation dysfunction (e.g., clotting factors deficiency, coagulation disorders or disorders), or a history of severe bleeding, or a history of massive bleeding after intramuscular injection or venipuncture, or a history of ecchymosis.
    1. Known medical history or diagnosis confirming that subjects have diseases affecting immune system function, including cancer, congenital or acquired immunodeficiency (e.g., infection with (HIV)), or uncontrolled disease.
    1. Serious or uncontrolled respiratory system disorders, cardiovascular disorders, nervous system disorders, blood and lymphatic system disorders, liver and kidney disorders, metabolism and skeletal disorders, etc. influencing study results evaluation at the investigator's discretion.
    1. Asplenia or functional asplenia.
    1. Long-term use (continuous use for ≥14 days) of or other immunomodulators (e.g., : prednisone or equivalents) within 6 months prior to administration of this investigational vaccine, except for topical medications (e.g., ointments, eye drops, inhalants or nasal sprays). And the topical medications should not exceed the recommended dose in the labels or induce any signs of systemic exposure.
    1. Having received immunoglobulins and/or blood products within 3 months prior to administration of this investigational vaccine.
    1. History of tuberculosis treatment or currently on antikoch's treatment for tuberculosis, whether pulmonary or extrapulmonary.
    1. Suspected or known alcohol dependency or drug abuse, which may affect safety evaluation or subject's compliance at the investigator's discretion.
    1. Planning to permanently move from the local area before study completion or leave the local area for a long time during the period of study visits.
    1. An employee of the study site, Sponsor and contract research organization (CRO) taking part in the study.
    1. Other conditions unsuitable for this study at the investigator's discretion.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Inactivated COVID-19 vaccines cohort group 1

    Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment, N=100 Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)

    Biological: Recombinant COVID-19 variant Vaccine (Sf9 Cell)

  • Active comparator
    Inactivated COVID-19 vaccines cohort group 2

    Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment, N=100 Intervention: COVID-19 Vaccine (Vero Cell), Inactivated

    Biological: COVID-19 Vaccine (Vero Cell), Inactivated

  • Experimental
    mRNA COVID-19 vaccines cohort group 1

    Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)

    Biological: Recombinant COVID-19 variant Vaccine (Sf9 Cell)

  • Active comparator
    mRNA COVID-19 vaccines cohort group 2

    Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: mRNA COVID-19 vaccine (Moderna)

    Biological: mRNA COVID-19 vaccine (Moderna)

  • Experimental
    Viral Vector COVID-19 vaccines cohort group 1

    Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)

    Biological: Recombinant COVID-19 variant Vaccine (Sf9 Cell)

  • Active comparator
    Viral Vector COVID-19 vaccines cohort group 2

    Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: Viral Vector COVID-19 vaccine (AstraZeneca)

    Biological: Viral Vector COVID-19 vaccine (AstraZeneca)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of adverse drug reactions (ADRs)

    Time frame: Day 0-28 post-boost dose

  2. GMT and SCR of specific neutralizing antibody (virus or pseudovirus) against SARS-CoV-2

    Time frame: Day 14 post-boost dose

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Day 0-7 post-boost dose

  2. Incidence of AEs

    Time frame: Day 0-28 post-boost dose

  3. Incidence of serious adverse events (SAEs)

    Time frame: Day 0 through 6 months post-boost dose

  4. GMT and SCR of specific neutralizing antibody (virus or pseudovirus) against SARS-CoV-2

    Time frame: Day 28, month 3 and month 6 post-boost dose

  5. GMI of specific neutralizing antibody (virus or pseudovirus) against SARS-CoV-2

    Time frame: Day 14, Day 28, month 3 and month 6 post-boost dose

  6. GMT, GMI and SCR of IgG antibodies against Vac2107 of SARS-CoV-2

    Time frame: Day 14, Day 28, month 3 and month 6 post-boost dose

Other outcomes

  1. GMT, GMI, and SCR of specific neutralizing antibody (virus or pseudovirus) against SARS-CoV-2 endemic variants

    Time frame: Day 14, Day 28, month 3 and month 6 post-boost dose

07

Study locations

1 site
  • Clínica de Enfermedades Crónicas y de Procedimientos Especiales, S.C.
    Morelia, Michoacán De Ocampo 58290, Mexico
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Nov 2024, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2022
First posted
Jul 20, 2022
StartActual
Jul 7, 2023
Primary completionEst.
Nov 30, 2024
CompletionEst.
Dec 2024
Last update
Mar 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05465902
Lead sponsor
WestVac Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Jul 20, 2022
Start date
Jul 7, 2023
Primary completion
Nov 30, 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Mar 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion